Log In
BCIQ
Print this Print this
 

brigatinib (AP26113)

  Manage Alerts
Collapse Summary General Information
Company Ariad Pharmaceuticals Inc.
DescriptionDual inhibitor of anaplastic lymphoma kinase (ALK) and EGFR
Molecular Target Anaplastic lymphoma kinase (ALK) ; Epidermal growth factor receptor (EGFR)
Mechanism of ActionAnaplastic lymphoma kinase (ALK) inhibitor; Epidermal growth factor (EGF) receptor inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC); Treat anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) in patients who are resistant to crizotinib; Treat metastatic ALK-positive non-small cell lung cancer (NSCLC) in patients who have progressed on crizotinib; Treat non-small cell lung cancer (NSCLC)
Regulatory Designation U.S. - Breakthrough Therapy (Treat anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) in patients who are resistant to crizotinib);
U.S. - Priority Review (Treat metastatic ALK-positive non-small cell lung cancer (NSCLC) in patients who have progressed on crizotinib)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/19/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today